Drug intelligence / Profile preview

SPEDOXDOC

Development stage: Phase 3
Lead developer: Sunstate Biosciences
Modality: Small Molecules, Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

SPEDOXDOC is a preclinical-stage combination nanodrug developed by Sunstate Biosciences using its proprietary Single Protein Encapsulation (SPE) platform. It consists of doxorubicin (a topoisomerase II inhibitor and DNA intercalator) and docetaxel (a microtubule-stabilizing agent) co-encapsulated within human serum albumin (HSA) without chemical modifications or nanoparticle assembly. This formulation is designed to enhance the therapeutic efficacy of both chemotherapeutic agents while reducing systemic toxicities, such as cardiotoxicity and myelosuppression, by leveraging the neonatal Fc receptor (FcRn)-mediated cellular recycling pathway of albumin in tumor tissues.

Targets

DNATOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on SPEDOXDOC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPEDOXDOC.